Join the Kisqali group to help and get support from people like you.
Kisqali News
Ribociclib + Nonsteroidal Aromatase Inhibitor Benefits Early Breast Cancer
THURSDAY, March 21, 2024 – Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) significantly improves invasive disease-free survival among patients with hormone receptor (HR)-positive, human...
American Society of Clinical Oncology, June 2-6
The annual meeting of the American Society of Clinical Oncology was held from June 2 to 6 in Chicago and attracted more than 34,000 participants from around the world, including clinicians,...
FDA Medwatch Alert: Drug Safety Communication: Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) - Rare but Severe Lung Inflammation
September 13, 2019 ISSUE: FDA is warning that Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) used to treat some patients with advanced breast cancers may cause rare but ...
Kisqali (ribociclib) Approved for Additional Indications in HR+/HER2- Advanced Breast Cancer
Basel, July 18, 2018 - Novartis today announced a new approval for Kisqali (ribociclib) from the US Food and Drug Administration (FDA) for women with hormone-receptor positive, human epidermal growth...
FDA Approves Kisqali (ribociclib) for HR+/HER2- Metastatic Breast Cancer
Basel, March 13, 2017 - The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Breast Cancer, Metastatic, Breast Cancer